Please use this identifier to cite or link to this item: https://scholarbank.nus.edu.sg/handle/10635/130568
DC FieldValue
dc.titleReoPro Observational Registry (RAPOR): Insights from the multicentre use of abciximab in Asia
dc.contributor.authorPoh, K.K.
dc.contributor.authorTan, H.C.
dc.contributor.authorYip, J.W.L.
dc.contributor.authorLim, Y.T.
dc.date.accessioned2016-11-17T08:38:42Z
dc.date.available2016-11-17T08:38:42Z
dc.date.issued2005-08
dc.identifier.citationPoh, K.K., Tan, H.C., Yip, J.W.L., Lim, Y.T. (2005-08). ReoPro Observational Registry (RAPOR): Insights from the multicentre use of abciximab in Asia. Singapore Medical Journal 46 (8) : 407-413. ScholarBank@NUS Repository.
dc.identifier.issn00375675
dc.identifier.urihttp://scholarbank.nus.edu.sg/handle/10635/130568
dc.description.abstractIntroduction: The pattern of use of abciximab in real-life clinical patients undergoing percutaneous coronary intervention (PCI) in 11 high-volume centres in Singapore, Malaysia, Thailand, Philippines, India, Pakistan and Korea was prospectively examined. Methods: These centres enrolled 224 consecutive patients over eight months to receive abciximab during PCI for the study. The cohort consisted of 82.1 percent males, with mean age of 55 (±11) years and mean weight of 67 (±17) kg. Results: The use of abciximab during PCI ranged between 6.2 percent and 21.6 percent. The indications for the use of abciximab were: acute coronary syndromes (34.3 percent), complex coronary lesions (17.9 percent) and multivessel PCI (17.7 percent). Based on a risk scoring system devised for this registry, majority (60.0 percent) of the patients was considered high risk when abciximab was used. Among the patients enrolled, 36.6 percent received abciximab as a "bail-out". The overall in-hospital ischaemic event rates were low at 4.0 percent. The complication rates included major bleeding 0.7 percent, thrombocytopenia 2.7 percent and need for blood transfusion 2.8 percent. There was a trend towards a higher incidence of in-hospital non-Q myocardial infarction in the "bail-out" group (2.1 percent versus 7.3 percent, p-value equals 0.07). Conclusion: Abxicimab was uncommonly used among patients (9.4 percent) undergoing PCI in this Asian region, with the operators reserving it mainly for high-risk patients.
dc.sourceScopus
dc.subjectAbciximab
dc.subjectAdjuvant drug therapy
dc.subjectAngioplasty
dc.subjectCoronary disease
dc.subjectPercutaneous coronary intervention
dc.typeArticle
dc.contributor.departmentMEDICINE
dc.description.sourcetitleSingapore Medical Journal
dc.description.volume46
dc.description.issue8
dc.description.page407-413
dc.description.codenSIMJA
dc.identifier.isiutNOT_IN_WOS
Appears in Collections:Staff Publications

Show simple item record
Files in This Item:
There are no files associated with this item.

Page view(s)

88
checked on Jul 19, 2019

Google ScholarTM

Check


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.